AI x Bio's wild week: phages in a patient, 32-minute drug leads, OpenAI buys Orchestra Bio
HealthcareAIGuy · x · 2026-10-23
AI x bio had an insane week across the whole stack:
- Models & protein design: Radical Numerics' Omnii-1 designed phages given to a human patient; Claude produced 17 lab-validated scorpion-toxin binders; open programmable protein design model RFD4-Proteina shipped
- Deals & pipelines: OpenAI acquired Orchestra Bio and, with PerturbAI, agents found new neurodegeneration leads in 32 minutes
- Simulation & agents: BioEmu2 biomolecular simulation model, Chaperone agent framework connecting 50+ protein design tools, Xaira's X-Scientist for agentic drug discovery
- Pharma adoption: Boltz with BMS and Phylo with Bayer deploying biomolecular models in pharma workflows; ex-OpenAI Kevin Weil launched Warp Sciences (AI + robotic labs)
- Also: Sophont's Holon-S1 predicts gene activity from pathology slides; open DNA model Carbon-X claims GPT-6.1 Sol-level performance at 1,000x lower cost
The author's takeaway: bio is becoming computer.
Related event: AI×Bio Week: AI-Designed Phage Used in Human Patient for First Time(4 posts)→
More from Venture
- AI workflow optimization startup Ridgeway acquired by senior-tech platform Chapter — hamostaf04 · 2026-10-23
- AI surfaces broke SEO ROI modeling — execs must fund content without clear returns — gaganghotra_ · 2026-10-23
- AI stocks dip just ~3% despite 'Black Thursday' panic headlines — JensHonack · 2026-10-23
- Fewer than 1% of Black Friday purchases will be agentic, predicts SEO expert Gagan Ghotra — gaganghotra_ · 2026-10-23
- OpEra launches AI decision engines, cuts retailer delivery costs 38% — ycombinator · 2026-10-23
- Robot data startup Maxinsights raises $30M seed, launches tactile data glove MaxGlove — heyshrutimishra · 2026-10-23